MOTS-c is a remarkable little molecule for one reason before you even get to what it does: it is encoded by your mitochondria, not by your main DNA. Mitochondria are the tiny power plants inside every cell, and they carry their own small loop of DNA. Tucked inside one of its genes is the recipe for MOTS-c — a peptide just 16 amino acids long. It is studied mainly as a metabolism regulator and a possible "exercise mimetic" (a molecule that copies some of exercise's benefits). Almost all of the convincing evidence, though, is from mice and cells.
In plain terms: a peptide your power plants make, studied as a bottled-exercise idea — mostly in animals so far.
What it is
MOTS-c stands for "mitochondrial open reading frame of the 12S rRNA type-c." Unpacking that: it is a short protein hidden inside a mitochondrial gene that was long assumed to only make part of the mitochondrial machinery. Researchers found it also codes for this signalling peptide1. It belongs to a small, newer family called mitochondrial-derived peptides.
Unusually, MOTS-c does not just act inside the mitochondria. Under stress it can travel to the cell nucleus and influence which genes are switched on — a mitochondria-to-nucleus message about the cell's energy state.
How it works: the AMPK switch
The core mechanism is an enzyme called AMPK. Think of AMPK as the cell's low-fuel warning light: when energy runs low, AMPK switches on and tells the cell to burn glucose and fat for energy rather than store them.
In mouse and cell studies, MOTS-c activates AMPK1. The downstream effects reported include better insulin sensitivity (cells respond more efficiently to insulin), improved glucose handling, and resistance to diet-induced weight gain.
In plain terms: in animals it flips the "burn fuel" switch — a lot like what exercise does.
Pharmacokinetics: short-lived
MOTS-c is a small peptide, and small peptides are cleared quickly. It has no long, weekly-style half-life (the time for half a dose to clear); circulating levels are measured in picograms and turn over rapidly. There is no established human pharmacokinetic profile for injected MOTS-c, because it has not been through that kind of trial. What is measured in humans is the body's own MOTS-c, not an injected dose.
What the studies actually found
The MOTS-c story built from a landmark discovery paper, through aging and exercise work in mice, to observational human measurements. Note the species and level in every row:
| Study | Model / level | Key result | Year |
|---|---|---|---|
| Lee et al.1 | Mice + muscle cells | MOTS-c activated AMPK, improved insulin sensitivity, and resisted diet-induced obesity | 2015 |
| Reynolds et al.2 | Aged mice + human muscle | Restored running capacity in old mice; acute exercise raised muscle MOTS-c ~12-fold in men | 2021 |
| Alser et al.3 | Humans (n=105, observational) | Serum MOTS-c and humanin were tightly correlated in athletes but not sedentary controls | 2022 |
Read the columns carefully. The dramatic "doubled running capacity" and "reversed insulin resistance" headlines come from mouse studies12. The human side is observational: exercise raises the MOTS-c your own body makes2, and blood levels track with fitness3 — but nobody has run a trial that injects MOTS-c into people and measures what happens.
In plain terms: strong, exciting mouse data; interesting but correlational human data; zero interventional human trials.
Handling and format
MOTS-c is supplied for research as a lyophilised (freeze-dried) powder that is reconstituted before use, and peptides of this class are generally kept cold and out of light once mixed — standard peptide-handling practice. This page explains what MOTS-c is and what the studies showed, not how to use it, and it takes no position on sourcing.
The honest limitations
- The efficacy evidence — metabolism, weight, exercise capacity — is preclinical, from mice and cells.
- Human data is observational: it measures natural MOTS-c, not an injected dose.
- No controlled human trial of MOTS-c as a treatment has been completed.
- It is a research compound, not an approved medicine anywhere.
Latest research
- The 2015 discovery paper remains the foundation: MOTS-c as an AMPK-activating metabolic regulator in mice and cells1.
- The 2021 aging study is the standout: a course of MOTS-c restored physical capacity in old mice, and the same paper showed human exercise sharply raises muscle MOTS-c — the strongest bridge yet between the peptide and exercise, still short of an injection trial2.
- 2022 human observational work confirmed circulating MOTS-c tracks with training status3, reinforcing the biomarker story while the interventional question stays open.
The short version
MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA that activates the energy-sensor AMPK and behaves, in animals, like a partial exercise mimetic — improving glucose handling and, in old mice, running capacity. In humans, exercise raises the body's own MOTS-c, but injectable MOTS-c has never been tested in a trial. The strong evidence is preclinical, and it is a research compound, not a medicine. Educational overview only. For context, see what are research peptides.